Why the study?
Does intravenous UK 14,275 improve inotropic activity in patients with suspected coronary artery disease?
Does intravenous UK 14,275 improve inotropic activity in patients with suspected coronary artery disease?
Answers are grounded in this paper and cite their sources.
The phosphodiesterase inhibitor UK 14,275 demonstrates significant inotropic effects without chronotropic action, suggesting potential utility in low cardiac output states.
A phosphodiesterase inhibitor, UK 14,275 (Pfizer) was administered intravenously to six patients with suspected coronary artery disease under-going diagnostic cardiac catheterisation to assess its inotropic activity. 2. Intracardiac haemodynamic measurements included pulmonary and systemic arterial pressure. Left ventricular end diastolic pressure and left ventricular dP/dtmax were also measured, in addition to cardiac output using the indocyanine green dye technique. 3. UK 14,275 resulted in a significant increase in LV dP/dtmax and cardiac output. 4. No chronotropic action was observed using this agent. 5. This agent may have potential therapeutic value in the management of cardiovascular failure associated with low cardiac output.
No takes yet. Share an insight, caveat, or question.
Jennings et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: